Frontiers in Cardiovascular Medicine (Apr 2023)

Phospholamban R14del disease: The past, the present and the future

  • Elizabeth Vafiadaki,
  • Pieter C. Glijnis,
  • Pieter A. Doevendans,
  • Pieter A. Doevendans,
  • Evangelia G. Kranias,
  • Evangelia G. Kranias,
  • Despina Sanoudou,
  • Despina Sanoudou,
  • Despina Sanoudou

DOI
https://doi.org/10.3389/fcvm.2023.1162205
Journal volume & issue
Vol. 10

Abstract

Read online

Arrhythmogenic cardiomyopathy affects significant number of patients worldwide and is characterized by life-threatening ventricular arrhythmias and sudden cardiac death. Mutations in multiple genes with diverse functions have been reported to date including phospholamban (PLN), a key regulator of sarcoplasmic reticulum (SR) Ca2+ homeostasis and cardiac contractility. The PLN-R14del variant in specific is recognized as the cause in an increasing number of patients worldwide, and extensive investigations have enabled rapid advances towards the delineation of PLN-R14del disease pathogenesis and discovery of an effective treatment. We provide a critical overview of current knowledge on PLN-R14del disease pathophysiology, including clinical, animal model, cellular and biochemical studies, as well as diverse therapeutic approaches that are being pursued. The milestones achieved in <20 years, since the discovery of the PLN R14del mutation (2006), serve as a paradigm of international scientific collaboration and patient involvement towards finding a cure.

Keywords